nutritional deficiency related, 12% myocarditis, 1% auto-immune myocarditis, 4% tachycardiomyopathy and 17% left ventricular non compaction (LVNC). Results: Mean age was 4.9±6.3, 56.6% were male. Normalization of left ventricular function was achieved in 39.8% of all patients. At the multivariate logistic regression non idiopathic DCM (HR 13, p=0.002) younger age (HR 0.87, p=0.04) and less necessity of inotropic support (HR 0.36, p=0.04) predicted normalisation of left ventricular performance. Overall, one and 5-year survival free from HT was 83.6% respectively 69.8%,survival rate was different according to the type of DCM (figure 1). Familiar history of cardiomyopathy or sudden death (HR 2.8, 95% CI 1.1-6.9, p=0.02) and inotropic support during hospitalisation hospitalisation (HR 4.4, 95% CI 1.1-9.8, p<0.001) where associated with a higher risk of death or HT. Figure 1 Conclusions: Overall, almost 40% of patients with DCM and severe LVD experienced a complete normalization of cardiac function during follow-up. Survival rate was extremely variable according to the type of DCM, to the presence of familiar history of cardiomyopathy or SD and to the severity of clinical presentation. 
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Background: Heart Failure comprises a wide range of patients classified according to the Ejection Fraction (EF). Patients with a Left Ventricular EF (LVEF) in the range of 40-49% represent a "grey area", defined as mid-range EF (HFmrEF) . Few data on the characteristics and outcomes of HFmrEF patients are available, mostly in the specific group of dilated cardiomyopathy (DCM). Aims: To define characteristics, evolution and prognosis of DCM patients with HFmrEF at diagnosis. Methods and results: From 1988 to 2013 we analysed 959 idiopathic DCM patients consecutively enrolled. One hundred and seventy-five (18%) fulfilled the criteria for HFmrEF, while 637 patients had a EF <40%. At baseline, compared with patients with reduced EF (HFrEF), HFmrEF presented features of a less advanced disease: lower NYHA III-IV classes (5 vs. 29% in HFmrEF vs. HFrEF group respectively, p<0.001), lower left bundle brach block (20 vs. 35%, p=0.001), less left ventricular end-diastolic volume (69 (59; 82) Background: Myocardial fibrosis has an impact on poor prognosis in patients with nonischemic dilated cardiomyopathy (NIDCM). The Selvester QRS score using twelve-lead electrocardiogram (ECG) has been reported to be associated with both amount of myocardial scar and poor prognosis in patients with myocardial infarction. However, little is known about its availability in patients with NIDCM. Purpose: The purpose of this study was to investigate the prognostic value of the Selvester QRS score and the association with collagen volume fraction (CVF) in patients with NIDCM. Methods: We enrolled 93 consecutive NIDCM patients (68 males, 53±13 years). Patients with permanent pacemaker or cardiac resynchronization therapy device were excluded. All patients were hospitalized in our institute for examination under each individual stable condition of heart failure (HF) and underwent twelve-lead ECG, echocardiography, right heart catheterization and endomyocardial biopsy. The CVF of biopsy specimen was measured by two observers in a blinded manner. The patients were divided into two groups based on the median value of the Selvester QRS score as follows; low score group (LS group, ≤3 points) (n=49) and high score group (HS group, >3 points) (n=44). Cardiac events were defined as a composite of cardiac death, hospitalization for worsening HF, and lethal arrhythmia. All patients were followed up for a mean of 4.4 years. Results: Means of left ventricular ejection fraction, plasma B-type natriuretic peptide level, the Selvester QRS score, and CVF were 32%, 185 pg/mL, 4.2 points and 3.36%, respectively. During the follow-up periods, 22 cardiac events were observed (cardiac death, n=1; hospitalization for worsening HF, n=12; lethal arrhythmia, n=9). In Kaplan-Meier survival analysis, the HS group had more cardiac Kaplan-Meier survival curves events than the LS group (log-rank, p=0.007) (Figure) . Cox proportional hazard regression analysis revealed that the Selvester QRS score was an independent determinant of cardiac events (hazard ratio, 1.21; 95% confidence interval, 1.04-1.40; p=0.02). In addition, mean of CVF was higher in the HS group (4.79%) than in the LS group (2.02%) (p<0.001) and there was a positive correlation between the Selvester QRS score and CVF (r=0.61, p<0.001).
Conclusions:
The Selvester QRS score is useful to predict future cardiac events in NIDCM, reflecting myocardial fibrosis assessed by CVF. Introduction: There are controversial data about the significance of the viral presence in the myocardium in recent onset dilated cardiomyopathy (RODCM). Furthermore, there were changes in the viral spectrum over time. Currently, parvovirus B19 (PVB19) marked prevalence is seen what distinctly contrasts with the situation in the past. Purpose: To evaluate the significance of the viral presence in the myocardium on the development of left ventricular ejection fraction (LVEF) in 1-year follow-up and on the presence of combined endpoint in 5-year follow-up. Patients and methods: 212 RODCM patients, 166 of them were males (78%), 46 females (22%). Mean age was 46.9±11.6 years, symptoms duration to diagnostic endomyocardial biopsy was 2.6±2.5 months, LVEF at baseline 24.1±7.1%, NYHA class 2.3±0.6. Combined mortality-morbidity endpoint was defined as the presence of death, resuscitation for cardiac arrest, adequate ICD discharge, heart transplantation or implantation of mechanical circulatory support, unscheduled hospitalization or non-planned outpatient visit for cardiovascular reason. Results: In the group without viral presence (PCR-, n=79, i.e. 37% of the whole group) LVEF increased from 23.2±7.3% at baseline to 34.0±11.7% at one-year visit (p<0.001). In the group with viral presence (PCR+, n=133, i.e. 63% of all patients) LVEF changed from 24.7±6.9% to 36.6±12.7% in one-year follow-up (p<0.001). When comparing the change in LVEF between both groups, similar improvement in LVEF at the end of the follow-up was found (11.1±12.5% in PCRgroup vs 11.5±12.4% in PCR+ group; p=0.716). The endpoint was present in 56.6% of the patients in PCR-group and in 59.8% of PCR+ group (p=0.487) in 5-year follow-up. PVB19 accounted for 92% of all PCR positive cases. Conclusion: Viral presence in the myocardium had no effect on the development of echocardiographic parameters or prognosis of the patients with RODCM. Background and aim of the study: Dilated cardiomyopathy (DCM) may represent a sequela of acute or chronic myocarditis, either due to persistence of an infectious agent (usually a virus) or secondary autoimmune myocardial injury. Accurate virological analysis of endomyocardial biopsy (EMB) specimens in patients with DCM is thus of crucial importance. Therefore, we aimed to compare the results of polymerase chain reaction (PCR) analyses targeted to detect genomes of selected cardiotropic viruses in EMB specimens that were performed in 2 microbiological laboratories Methods: In 20 consecutive patients (52±12 years, 14 men) with recently diagnosed unexplained DCM (left ventricular ejection fraction 27±7%), EMB specimens were independently studied in 2 different microbiological laboratories (A and B) by using qualitative PCR that was focused on the detection of genomes of parvovirus B19 (PVB19) and herpesviruses including human herpesvirus type 6 (HHV6), human cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1 and 2 (HSV 1 and 2). Complete agreement between the laboratories was defined as detection of the same viral genomes or their complete absence by both laboratories; partial agreement was defined as detection of any of multiple viral genomes by one lab but not the other; all other scenarios were considered disagreement. Results: A viral genome was found in 12 patients (PVB19 in 11 subjects and HHV6 in 3 individuals) in lab A, and in 10 patients (PVB19 in 8 subjects, HHV6 in 3 subjects and CMV in 1 individual) in lab B. Complete agreement between 2 laboratories was present in 7 patients (35% of the whole study group) and there was no case of partial agreement.
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Conclusions:
The disagreement in PCR viral analysis in two thirds of cases shows large inter-laboratory variability in the assessment of EMB specimens in patients with recently diagnosed DCM. Microbiological laboratories involved in PCR diagnostics of viral persistence in DCM should regularly validate their methodology and undergo independent evaluation of their results. Background and aim: It is unknown whether the cardiac phenotype of left ventricular hypertrabeculation/noncompaction (LVHT) plays a prognostic role. Thus, aim of the study was to assess whether the prevalence of neuromuscular disorders (NMDs) and the prognosis of LVHT-patients regarding mortality or cardiac transplantation is dependent on the cardiac phenotype. Methods: Included were patients in whom LVHT was diagnosed between 1995-2016 in one echocardiographic laboratory. The cardiac phenotype was assessed as "dilated" if the left ventricular enddiastolic diameter (LVEDD) was >57mm and the left ventricular fractional shortening (FS) was <26%, as "hypertrophic" if the LVEDD was <58mm, the FS >25% and left ventricular posterior wall (LVPWT) as well as interventricular septal thickness (IVST) both were >13mm, as "intermediate" if LVEDD was >57mm and FS >25% or if LVEDD was <58mm und FS <26% and as "normal" if LVEDD was <58mm, FS >25%, and IVST and LVPWT <14mm. The pharmacotherapy, decision for electronic devices or cardiac transplantation was carried out by the treating physicians. In October 2016, it was assessed if the patient was alive or had undergone cardiac transplantation. Results: LVHT was diagnosed in 273 patients (80 females, age 53±16 years). One-hundred-ninety-six patients (72%) were investigated neurologically. A specific NMD was diagnosed in 16%, NMD of unknown etiology was diagnosed in 60%, and the neurological investigation was normal in 25%. The cardiac phenotype was assessed as dilated in 126 patients (46%), hypertrophic in 22 (8%), intermediate in 45 (17%) and as normal in 80 (29%). During a follow-up of 7.4 (±5.7) years, 59 patients received electronic devices (implanted cardioverter/defibrillator with cardiac resynchronization device n=18, implanted cardioverter/defibrillator n=17, antibradycardic pacemaker n=11, cardiac resynchronization device n=4, wearable defibrillator n=4, implanted loop recorder n=3, left ventricular assist device n=2). Eighty-four patients died and 6 underwent cardiac transplantation. The most frequent causes were heart failure (n=26), sudden death (n=13) and pneumonia (n=11). The mortality and rate of cardiac transplantation differed between the phenotypes and was highest in the dilated group and lowest in the hypertrophic group. Among the patients with the dilated phenotype the mortality differed between the patients with and without NMDs.
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Conclusion:
The prognosis of patients with LVHT is dependent on the cardiac phenotype. LVHT patients with the dilated phenotype have the worst prognosis. Among the patients with the dilated phenotype, prognosis is dependent on the presence or absence of a NMD. These findings are in accordance with other cohort studies which showed that prognosis of LVHT patients is dependent on systolic dysfunction and heart failure. It has to be assessed if close follow-up and special therapy may improve the prognosis of patients with the dilated type of LVHT. Introduction: In cardiac resonance imaging, the excess of trabeculae in the LV generates questions to make a diagnosis. Methods: 764 consecutive cardiac magnetic resonance (CMR) studies from a tertiary centre from 2003-2010 were reviewed: 67% men, age 41.3±17, 97% stent from cardiologist. The reason to request proof was cardiomyopathy (44%), arrhytmias (17%), ischemic (9%), myocarditis (7%). End-diastolic short axis images were anaylized. Left ventricular hypertrabeculation (LVHT) was considered when remarkable trabeculation was identified in ≥2 segments and in ≥2 consecutive slices. Non-compaction (LVNC) was considered when the ratio between trabecula and compacted layer was ≥2 (Jenni criteria) or ≥2.3 (Petersen criteria). Studies were classified into 4 categories according to the presence or absence of dilatation (D) or hypertrophy (H). Dilatation was defined as LVEDVol ≥105 ml/m 2 for men or 96 ml/m 2 for women, and Hypertrophy as maximal LV wall thickness ≥15 mm. Individuals could then have D+H, isolated D, isolated H or none of them. Results: 103 (13%) had LVHT, most of whom (53%) had normal LV ejection fraction (LVEF>50%). Half were non-D non-H hearts. The other half was distributed quite similarly between dilated, hypertrophic and hypertrophic-dilated cardiomyopathies. The prevalence of LVNC in our population was 6% (Jenni) and 5% (Petersen). Patients with LVNC according to Jenni criteria have predominantly (42%) a moderately depressed LVEF (40-50%), half (52%) of which were non-dilated or hypertrophic, and the other half distributed among the other cardiomyopathies with a higher prevalence of dilated (37%). Conclusions: In patients referred for magnetic resonance study, the proportion
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